Keywords
How to Cite
Abstract
It is presented the results of a randomized prospective study, which there was examined the influence of rIL-2 (“Ronkoleykin ®») on the effectiveness of the regime R-CHOP in first-line treatment of patients with B-cell non-Hodgkin’s lymphomas. From March 2006 to December 2009, the study included 109 newly diagnosed patients. Standard mode R-CHOP was used in 59 patients, in 50 was added rIL-2, which was injected subcutaneously with 1 million IU per day during each course in l-5th days.lt was found that the inclusion of rIL-2 in the R-CHOP regimen increased the effectiveness of the treatment of B-cell NHL with a high-risk of poor disease’s course.References
Пальцев М.А., Иванов А.А. Межклеточное взаимодействие. — М.: Медицина. — 1995. — 224 с.
Allison M.A., Jones S.E., McGuffy Phase I trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and Selected solid tumors // J. Clin. Oncol. — 1989. - Vol. 7. — P. 75-81.
Bernstein Z.P., Vaickus L., Friedman N. et al. Interlenkin-2 lymphokine aktivated killer cell therapy of non-Hodgkin’s lymphoma and Hodgkin’s disease // J. Immunother. — 1991. — Vol. 10. — P. 141-145.
Cemy T., Borisch B., Intona M. et al. Mechanismus of action of rituximab // Anticancer Drugs. — 2002. — Vol. 13. — P. 3-10.
Cheson B.D., Horning S.J., Coiffer B. et al. Report of an international work — shop to standardize response criteria for non -Hodgkin’s lymphoma // J. Clin. Oncol. — 1999. — Vol. 17. — P. 1244-1263.
Christopher S.N., Novick A.C., Tonnenbaum C.S. et al. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T—lymphocyte apoptosis and NFkB suppression // Urology. — 2002. — Vol. 59. — P. 9-14.
Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti -CD20 reagents // Blood. — 2004. — Vol. 103. - P. 2728-2743.
Dalle S., Dupire S., Brunet — Manquat S. et al. In vivo model of follicular lymphoma resistant to rituximab // Clin. Cancer Res. — 2009. — Vol. 15. — P. 851-857.
Dall’Ozzo S., Tartas S., Paintaund G. et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship // Cancer Res. — 2004. — Vol. 64. — P. 4664 -4669.
Eisenbeis C.F., Colegiuri M.A., Byrd J.S. Rituximab: Converging mechanisms of action in non -Hodgkin’s Lymphoma // Clin. Cancer Res. — 2003. — Vol. 9. — P. 5810-5812.
Eisenbeis C.F., Grainger A., Fisher B. et al. Combination immunotherapy of B-cell non-Hodgkin’s Lymphoma with rituximab and interleukin-2: a preclinical and phase I study // Clin. Cancer Res. — 2004. — Vol. 10. — P. 6101 -6110.
Foran J.M., Narton A.J., Micallef I.N. et al. Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis // Br. J. Haematol. — 2001. — Vol. 114. — P. 881-883.
Friedberg J.W., Neuberg D., Gribben J.G. et al. Combination immunotherapy with rituximab and interleukin-2 in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma // Brit. J. Haemathol. — 2002. — Vol. 117. — P. 828-834.
Gisselbrecht C., Maraninchi D., Pico J.L. et al. Interlenkin-2 treatment in lymphoma: a phase II multicenter study // Blood. — 2008. — Vol. 83. — P. 2081-2085.
Gluck W.L., Hurst D., Yuen A. et al. Phase I studies of interleukin (IL-2) and rituximab in B-cell non-Hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlates with clinical response // Clin. Cancer Res. — 2004. — Vol. 10. — P. 2553-2564.
Golay J., Lazzari M., Facchinetti V. et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD95 // Blood. — 2001. — Vol. 98. — P. 3383-3389.
Herold M., Pasold R., Srock S. et al. Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCR alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL) // Blood. — 2004. — Vol. 104. — Abs. 584.
Jazirehi A.R., Vega M.I., Bonavida B. Development of rituximab — resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy // Cancer Res. — 2007. — Vol. 67. — P. 1270-1281.
Khan K.D., Emmanouilides C., Be3nson D.M. et al. A. phase II study of rituximab in combination with recombinant interleukin-2 for rituximab — refractory indolent non-Hodgkin’s lymphoma // Clin. Cancer Res. — 2006. — Vol. 12. — P. 7046-7053.
Lopes de Menezes D.E., Denis-Mize K., Tang Y. et al. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin’s lymphoma // J. Immunother. — 2007. -Vol. 30. — P. 64-74.
Maeshima A.M., Taniguchi H., Nomoto J. et al. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin’s lymphoma after rituximab therapy // Cancer Sci. — 2009. — Vol. 100 — P. 54-61.
Marcus R., Solal — Gelingny P., Imrie K. et al. MabThera (Rituximab) plus cyclophosphamide, vincristine and prednisolone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non — Hodgkin’s Lymphoma (NHL) // Blood. — 2005. — Vol. 108. — Abs. 481.
Pfreunsdschuh M., Schubert J., Ziepert M. et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60) // Lancet Oncol. — 2008. — Vol. 9. — P. 105-116.
Vose J.M., Link B.K., Grossbard et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously intreated aggressive non -Hodgkin’s Lymphoma // J. Clin Oncol. — 2001. — Vol. 19 — P. 389-397.
Weisenburger F.K., Choi W.W., Perry K.D. et al. Addition of rituximab to standard chemotherapy improves the survival of bouth the germinal centr B-cell -like subtypes of diffuse large B-cell lymphoma // J. Clin. Oncol. — 2008. — Vol. 26. — P. 4587-4594.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...